Press release
curasan AG: Profits warning for 2010
Kleinostheim, Germany – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010.The reason for this is the contract agreement that has just been concluded for the sale of the oncological product Mitem® to the Speciality European Pharma Ltd. (SEP), London, and the extraordinary earnings associated with it. The sale will tentatively come into effect on 1st November.
It has been agreed to maintain silence regarding the value of the transaction.
curasan AG, thus, finalizes the concentration of the product portfolio in the biomaterials sector with the sale of the pharmaceutical drug Mitem®. The liquidity position of the company, which is very good anyway, will improve considerably as a result of this development.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
About Speciality European Pharma Ltd:
Founded in April 2006, SEP is a privately owned speciality pharmaceutical company. Its mission is to become the leading urology-focused speciality pharmaceutical business in Europe. SEP owns worldwide rights to PLENAXIS®. SEP has distribution rights in a number of European countries for Haemopressin®/Variquel®, a product for the treatment of Bleeding Oesophageal Varices. In the UK and Ireland, SEP also has the distribution rights to Regurin® for the treatment of overactive bladder. The new once daily formulation, Regurin® XL, was launched in September 2009.
SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.
To learn more about Speciality European Pharma, please visit www.specialityeuropeanpharma.com
curasan AG
Andrea Weidner
Lindigstraße 4
63801 Kleinostheim
Germany
Tel. 06027/40 900 51
Fax 06027/40 900 39
andrea.weidner@curasan.de
fr financial relations gmbh
Jörn Gleisner
Gutleutstraße 75
60329 Frankfurt/Main
Germany
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@financial-relations.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release curasan AG: Profits warning for 2010 here
News-ID: 146747 • Views: …
More Releases from curasan AG
curasan AG: Dental Business Unit acquired as of June 1
Kleinostheim, Germany, June 6, 2013 – curasan AG, Germany, has acquired a large part of the “Oral Regenerative Medicine” division of Riemser Pharma GmbH, Germany, effective June 1, 2013.
curasan AG now owns the marketing and distribution rights for the products covered by the contract and is assuming the sales structures, including the na-tional and international customer base.
As a result of this change, curasan has immediate access to the dental market…
curasan AG now sells bone regeneration material in injectable form
Kleinostheim, 05.12.2012 – curasan AG, listed on the General Standard (ISIN: DE 000 549 453 8), has introduced its new bone regeneration material CERASORB® Ortho Paste to the German and European markets at the beginning of December.
CERASORB® Ortho Paste is comprised of fine granules of the proven, fully resorbable, synthetic material CERASORB® M Ortho suspended in a hyaluronic acid hydrogel-matrix. The paste-like product has the advantage that it is…
curasan AG commences operations in the European market with the appointment of a …
Kleinostheim, 15.02.2012 – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8), created a new post on 1st February 2012 in relation to the active expansion of its European sales network in the fields of Orthopaedics and trauma surgery. Mr. Lee McCann BSc Business Administration (North West University of Applied Science, London, U.K.), will be operating as the organisation’s International Sales Director for Orthobiologics with immediate…
curasan AG: Novel bone regeneration material approved for sale in Europe
Kleinostheim, Germany – curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material.
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate…
More Releases for SEP
Brilliance SF Reviews - [Sep - 2021] "No.1 Cream" Get Special Discount!
Brilliance SF Collagen Retinol Cream has actually been introduced in the market with the goal of repairing the majority of the skincare issues that are being dealt with by a lot of females in this establishing world. With the exposure to endless contaminants, a life filled with anxiety, as well as a diet plan that isn't as healthy, as it made use of to be, the one major organ of…
Max Thrive Keto Reviews : (UPDATED SEP 2021) Negative Reviews and Side Effects R …
Max Thrive Keto Reviews: - You want to become healthy and slim again. Yet if you want your weight loss results to thrive, you need the breakthrough ketogenic diet plan and a powerful support supplement like limit Thrive Keto Pills. With this effective combination, you can lastly get the nutrients that your body requires to enhance your metabolism and also help you lose weight for good. In this way, you…
Get Bright Brain Education Festival Sep 2020
National Online Learning Event Features 15 Mindfulness Experts, Sep 11-13, 2020
September 8, 2020 -- Body & Brain is proud to announce the online Get Bright Brain Education Festival! Join us for three days of exciting live online seminars with an all-star lineup of 15 Brain Education mindfulness coaching experts.
The Festival will be held on Friday, September 11 through Sunday, September 13, 2020 from 7am-4:10pm (PDT) / 10am-7:10pm (EDT). Five unique…
RTI Webinar Sep 8: How to Design Distributed Robotic Control Systems
SUNNYVALE (USA)/London, September 2016 – Topic of the new webinar from Real-Time Innovations (RTI), in partnership with Energrid, is how to design Distributed Robotic Control Systems. On September 8 at 1 p.m. (CET), the webinar can be followed for free via RTI website www.rti.com.
Within the 60 minutes webinar, the experts Dr. Edwin de Jong, Vice President of Sales at RTI, and Doug Barker, Senior Robotic Systems Engineer at Energrid,…
Search Engine Poisoning (SEP) Fails to 'Meddle' with Olympic Search Queries
DUBAI, United Arab Emirates, September 11, 2012 – Following previous research into Search Engine Poisoning attacks, Blue Coat Systems, the market leader in Web security and WAN optimization solutions, today released its findings on this type of attack during the 2012 Olympic Games. The research has shown that of the 28,227 successful SEP attacks, which took place during the 26 days leading up to the Olympics and the first 13…
India’s 1st Social Search Optimization Workshop in Delhi on Sep 24
Delhi, India ( openpr ) September 16, 2010 - Digital Vidya is pleased to announce its first Social Search Optimization Bootcamp in Delhi on Sep 24. Professionals who are interested in multiplying the ROI of their Social Media and Search campaigns may want to be part of this event.
Aimed at Sales & Marketing professionals, SEO professionals, Social Media Marketers, CXO’s and Entrepreneurs, this 1-day hands-on workshop on Social Search will…
